Study guide

12.6 New or Experimental Treatments, Monitoring Patient Reactions, and Reporting Adverse Events

California Dental Law and Ethics Examination Dentistry Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation

1.1 Exam Format, Legal Sources, and the Board's Enforcement Tools

2 Chapter 2: Law — Patient Information and Records

2.1 Confidentiality and Releasing Patient Information 2.2 Documenting Treatment, Prescriptions, and Record Corrections 2.3 Storing, Securing, and Disposing of Records, Including When a Practice Closes 2.4 Responding to Unauthorized Access: Breach Notification Duties 2.5 Responding to Records Requests: Rights, Refusals, Deadlines, and Fees

3 Chapter 3: Law — Advertising, Postings, and Workplace Conduct

3.1 Advertising: Specialty Claims, Patient Images, Fees, Disclosures, and Fictitious Names 3.2 Documents That Must Be Posted or Displayed in a Dental Office 3.3 Sexual Harassment Law and a Respectful Workplace

4 Chapter 4: Law — Supervising Dental Auxiliaries

4.1 Supervision Levels, the Patient-of-Record Rule, and the Dentist's Responsibility 4.2 Auxiliary Scope of Practice: DA, OA, DSA, RDA, RDAEF, RDH, and RDHAP

5 Chapter 5: Law — Infection Control, Waste, and Medical Emergencies

5.1 California's Minimum Standards for Infection Control (16 CCR § 1005) 5.2 Hazardous Waste, Medical Waste, and Amalgam Disposal 5.3 Medical Emergency Preparedness: Emergency Kits, Cal/OSHA First Aid, and Training

6 Chapter 6: Law — Mandated Reporting of Abuse and Neglect

6.1 Reporting Suspected Child Abuse and Neglect (CANRA) 6.2 Reporting Elder and Dependent Adult Abuse, and Documenting Evidence

7 Chapter 7: Law — Scope of Practice, Permits, Patient Access, and Fees

7.1 The Dentist's Scope of Practice and Procedures That Need Extra Credentials 7.2 Sedation and General Anesthesia Permits Under SB 501 7.3 Protected Classes: Accepting, Dismissing, and Accommodating Patients 7.4 Fee Estimates, Billing Limits, and Patient Financing

8 Chapter 8: Law — Consent and Telehealth

8.1 Informed Consent, Informed Refusal, and Patients With Cognitive Impairment 8.2 Consent for Minors: Parents, Caregivers, Emancipation, and Self-Consent 8.3 Telehealth Law for Dentists: New Patients, Consent, and Security

9 Chapter 9: Law — Prescribing and Controlled Substances

9.1 CURES: Registration, the Duty to Consult, and the Exemptions Dentists Use Most 9.2 Opioids for Minors, Scope Limits on Prescribing, and Prescription Requirements

10 Chapter 10: Ethics — Patient Education and Shared Decisions

10.1 The Ethics Framework and Confirming Understanding Across Communication Barriers 10.2 Presenting Current Conditions and Treatment Options, and Disclosing Iatrogenic Changes 10.3 Future Care Needs: Risks of Non-Treatment, Material Misconceptions, and Realistic Expectations 10.4 Alternative Treatments and Shared Decisions When Several People Are Involved

11 Chapter 11: Ethics — Colleagues, Referrals, Continuity, and Emergencies

11.1 Discussing Another Dentist's Work, and When to Report Other Professionals 11.2 Referring Patients: Competence, Medical Consultation, Professional Networks, and Referral Payments 11.3 Managing Referred Patients: Continuity, Autonomy, and Gifts From Specialists 11.4 Continuity of Care: Dismissing Patients, Interruptions, New-Patient Records, and Relocation 11.5 Emergency Treatment: Access During and After Business Hours

12 Chapter 12: Ethics — Telehealth, Billing, Impairment, Exposure, and Standard of Care

12.1 Telehealth Ethics: When It Fits, How to Deliver It, and Honest Dates on Claims 12.2 Insurance Billing Ethics: Accurate Claims, Fees, Copayments, and Codes 12.3 Dentist Impairment and the Dental Board's Diversion Program 12.4 Bloodborne Pathogen Exposure: Informing Patients and Disclosing the Dentist's Status 12.5 Standard of Care: Overtreatment, Unnecessary Treatment, and Undertreatment 12.6 New or Experimental Treatments, Monitoring Patient Reactions, and Reporting Adverse Events

12.6 New or Experimental Treatments, Monitoring Patient Reactions, and Reporting Adverse Events

Key Takeaways Explain This Topic AI

California B&P § 651(b)(7) makes a scientific claim misleading if it cannot be supported by reliable, peer-reviewed, published studies.

ADA Advisory Opinion 5.D.2 requires dentists to verify a health product's safety and efficacy claims independently, not rely on the manufacturer.

California requires an experimental subject's bill of rights and a signed, dated written consent before a medical experiment (Health and Safety Code §§ 24172–24173).

ADA Advisory Opinion 5.D.1 obliges a dentist who suspects an adverse reaction to a drug or device to tell the medical and dental community, including the FDA for serious events.

California Civil Code § 56.10(c)(14) permits disclosing patient information when voluntarily reporting drug or device adverse events to the FDA.

Last updated: September 2026

Evaluating new or experimental treatment (K2171)

A dentist considering a new laser protocol, a novel implant surface, a "biomimetic" material, or an off-label use should apply clear criteria:

Criterion Question to ask Source

Evidence Is there reliable, peer-reviewed, published research, ideally systematic reviews or controlled trials, rather than case reports or testimonials? B&P § 651(b)(7); ADA 5.A.2

Independent verification Have I checked the manufacturer's claims myself, not just accepted their marketing? ADA 5.D.2

Regulatory status Is the device FDA-cleared or approved for this use? Is the use off-label, and is that disclosed? FDA; veracity

Transparency Are the complete formulae available to the profession, and am I avoiding claims of exclusive or secret methods? ADA 5.D

Competence Have I completed adequate training, and can I manage complications? ADA 2.A; CDA competence

Consent Have I told the patient the treatment is new or experimental, what the evidence shows, the risks and unknowns, and the established alternatives? Cobbs ; CDA 1D

Conflicts Do I have a financial interest to disclose? ADA 5.C, 5.D.2

ADA Section 5.D requires dentists, except in formal investigative studies, to prescribe, dispense, or promote only devices, drugs, and agents whose complete formulae are available to the profession, and not to hold out any device or technique as exclusive if that would be misleading. Advisory Opinion 5.A.2 calls it unethical to claim a treatment can diagnose, cure, or relieve conditions without accepted scientific support.

Formal research

When a treatment is part of a medical experiment , California's Protection of Human Subjects in Medical Experimentation Act requires:

An experimental subject's bill of rights , in a language the subject speaks fluently, covering the purpose, procedures, discomforts and risks, expected benefits, alternatives , treatment available if complications arise, the chance to ask questions, the right to withdraw at any time without prejudice, a copy of the signed consent, and a decision free of coercion (Health and Safety Code § 24172).

A written consent form , signed and dated by the subject or legal representative (§ 24173).

The CDA Code (Section 1D) likewise requires informed consent before using a human subject in research. ADA Section 3.C obliges dentists to share useful research results with the profession.

Evaluating patient reactions (K2174)

Monitoring does not end when the patient leaves the chair. Evaluate reactions systematically:

Baseline: record allergies, including latex, local anesthetics, metals, acrylics, and medications, along with current drugs and relevant conditions.

During treatment: watch vital signs and responses, especially with anesthetics, sedation, and new materials.

Afterward: follow up after surgery, new prescriptions, or new materials by phone or recall, and ask specifically about symptoms.

Assess causation: timing, dose, prior exposure, whether symptoms improve when the agent is removed, and other possible causes.

Classify severity: expected side effect, such as mild post-operative sensitivity; allergic reaction, such as a mucosal lichenoid reaction to a metal; or serious adverse event , such as anaphylaxis, hospitalization, permanent nerve injury, or death.

Act: treat or refer, change the plan, document in the chart, update the allergy list, and inform the patient.

Reporting adverse reactions (T211, K2111)

ADA Advisory Opinion 5.D.1:

A dentist who suspects the occurrence of an adverse reaction to a drug or dental device has an obligation to communicate that information to the broader medical and dental community, including, in the case of a serious adverse event, the Food and Drug Administration (FDA).

Ways to meet it:

FDA MedWatch: voluntary reports by health professionals of serious adverse events, product problems, and device malfunctions. Civil Code § 56.10(c)(14) expressly permits disclosing medical information for voluntary FDA reports.

Vaccine Adverse Event Reporting System (VAERS): for dentists who give influenza or COVID-19 vaccines (Section 7.1), report clinically significant adverse events after vaccination.

The manufacturer: so it can investigate and meet its own FDA reporting duties.

Colleagues: case reports, study clubs, and dental society channels, with patient identity protected.

The Dental Board, when the law requires it: a patient's death , or a hospital or emergency transfer (always, for sedated patients), must be reported within seven days (B&P § 1680(z)). This is a legal report, separate from the ethical duty to inform the community.

Worked scenario

Three patients develop persistent, unusual gingival inflammation around restorations placed with a newly marketed resin cement. Symptoms improve after the restorations are replaced with a different cement.

Evaluate each case, document the timeline and response, and tell the patients what was found.

Stop using the product pending review.

Report to the manufacturer and file an FDA MedWatch report (ADA 5.D.1). If a reaction is serious, the FDA report is expressly expected.

Share the observation with colleagues through appropriate professional channels, without identifying patients.